New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris

Thomas Vogl; Franz Stefan Hartner; Anton Glieder

doi:10.1016/j.copbio.2013.02.024

New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris

Thomas Vogl, Franz Stefan Hartner, Anton Glieder^*

^*Corresponding author for this work

Institute of Molecular Biotechnology (6550)

Research output: Contribution to journal › Article › peer-review

Abstract

Biopharmaceuticals are an integral part of modern medicine and pharmacy. Both, the development and the biotechnological production of biopharmaceuticals are highly cost-intensive and require suitable expression systems. In this review we discuss established and emerging tools for reengineering the methylotrophic yeast Pichia pastoris for biopharmaceutical production. Recent advancements of this industrial expression system through synthetic biology include synthetic promoters to avoid methanol induction and to fine-tune protein production. New platform strains and molecular cloning tools as well as in vivo glycoengineering to produce humanized glycoforms have made P. pastoris an important host for biopharmaceutical production.

Original language	English
Pages (from-to)	1094-1101
Journal	Current Opinion in Biotechnology
Volume	24
Issue number	6
DOIs	https://doi.org/10.1016/j.copbio.2013.02.024
Publication status	Published - 2013

Fields of Expertise

Human- & Biotechnology

Treatment code (Nähere Zuordnung)

Review

Access to Document

10.1016/j.copbio.2013.02.024Licence: CC BY-NC-ND 3.0

Cite this

@article{4bd88ce11f1346a1b99e19aa3693346a,

title = "New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris",

abstract = "Biopharmaceuticals are an integral part of modern medicine and pharmacy. Both, the development and the biotechnological production of biopharmaceuticals are highly cost-intensive and require suitable expression systems. In this review we discuss established and emerging tools for reengineering the methylotrophic yeast Pichia pastoris for biopharmaceutical production. Recent advancements of this industrial expression system through synthetic biology include synthetic promoters to avoid methanol induction and to fine-tune protein production. New platform strains and molecular cloning tools as well as in vivo glycoengineering to produce humanized glycoforms have made P. pastoris an important host for biopharmaceutical production.",

author = "Thomas Vogl and Hartner, {Franz Stefan} and Anton Glieder",

year = "2013",

doi = "10.1016/j.copbio.2013.02.024",

language = "English",

volume = "24",

pages = "1094--1101",

journal = "Current Opinion in Biotechnology",

issn = "1879-0429",

publisher = "Elsevier Ltd.",

number = "6",

}

TY - JOUR

T1 - New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris

AU - Vogl, Thomas

AU - Hartner, Franz Stefan

AU - Glieder, Anton

PY - 2013

Y1 - 2013

N2 - Biopharmaceuticals are an integral part of modern medicine and pharmacy. Both, the development and the biotechnological production of biopharmaceuticals are highly cost-intensive and require suitable expression systems. In this review we discuss established and emerging tools for reengineering the methylotrophic yeast Pichia pastoris for biopharmaceutical production. Recent advancements of this industrial expression system through synthetic biology include synthetic promoters to avoid methanol induction and to fine-tune protein production. New platform strains and molecular cloning tools as well as in vivo glycoengineering to produce humanized glycoforms have made P. pastoris an important host for biopharmaceutical production.

AB - Biopharmaceuticals are an integral part of modern medicine and pharmacy. Both, the development and the biotechnological production of biopharmaceuticals are highly cost-intensive and require suitable expression systems. In this review we discuss established and emerging tools for reengineering the methylotrophic yeast Pichia pastoris for biopharmaceutical production. Recent advancements of this industrial expression system through synthetic biology include synthetic promoters to avoid methanol induction and to fine-tune protein production. New platform strains and molecular cloning tools as well as in vivo glycoengineering to produce humanized glycoforms have made P. pastoris an important host for biopharmaceutical production.

U2 - 10.1016/j.copbio.2013.02.024

DO - 10.1016/j.copbio.2013.02.024

M3 - Article

SN - 1879-0429

VL - 24

SP - 1094

EP - 1101

JO - Current Opinion in Biotechnology

JF - Current Opinion in Biotechnology

IS - 6

ER -

New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris

Abstract

Fields of Expertise

Treatment code (Nähere Zuordnung)

Access to Document

Fingerprint

Cite this